ImmunityBio, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings reports show if a company is making progress and managing money well.
Government approval to sell a drug in a new country expands where the company can make money.
Directors oversee company decisions, so who shareholders choose matters to business direction.
New business agreements can create revenue growth or strategic advantages for the company.
Quarterly earnings reports show if a company is making progress and managing money well.
Auditors check that financial statements are honest, protecting investors from misleading information.
Stocky reads ImmunityBio, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
ImmunityBio, Inc.'s most recent tracked filing was a 10-Q on 4 Aug 2026: Q2 2026 financial results and business update released.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.